DailyDoctor Archive Specialties Get app
Back to the 7 October 2026 edition

Practice changer · 05 of 05

Start an alpha-blocker at catheterisation for BPH-related retention

Start an alpha-blocker when catheterising for BPH-related retention; it raised trial-without-catheter success by about a quarter.

Design
Systematic review and meta-analysis of 8 randomised controlled trials
Population
Men with acute urinary retention due to benign prostatic hyperplasia
Primary outcome
Successful trial without catheter
Effect
Risk difference +24.5% (95% CI 18.4 to 30.7) vs placebo

A meta-analysis of eight randomised trials compared alpha-blockers with placebo in men with acute urinary retention due to benign prostatic hyperplasia, before a trial without catheter.

Alpha-blockers increased the chance of voiding successfully by an absolute 24.5 percentage points — roughly one extra successful trial for every four men treated. The authors report a possible reduction in recurrent retention and no significant increase in adverse effects.

This confirms what many urologists already do but is not yet universal, particularly in emergency departments and general wards where catheters are placed. Starting the alpha-blocker at catheterisation, rather than waiting for the urology review, gives it time to work before the trial without catheter, usually a few days later. Watch for postural hypotension in older men.

  • Start an alpha-blocker such as tamsulosin or alfuzosin when catheterising a man for BPH-related retention.
  • Plan a trial without catheter after a few days of treatment rather than immediately.
  • Warn about dizziness on standing, especially in older men and those on antihypertensives.
  • Continue the alpha-blocker after a successful trial and arrange urology follow-up.
  • Ask about planned cataract surgery; alpha-blockers can cause floppy iris syndrome.

Why it matters

A simple prescription at the first contact roughly prevents one failed trial without catheter for every four men treated.

The statistics, in plain English

A risk difference of 24.5% (95% CI 18.4 to 30.7) is an absolute gain, so the number needed to treat for one extra success is about 4. The pooled trials varied in drug, dose and timing.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

incontinenceuroandrologyprostatecancerbph

Tomorrow morning, before your first patient

One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app